Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia-Reference-Cited by-同舟云学术

Poor prognosis of SRSF2 gene mutations in patients treated with VEN-AZA for newly diagnosed acute myeloid leukemia

Published:2024-06 Issue: Volume:141 Page:107500
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Berton Guillaume,Sedaki Bochra,Collomb Erwann,Benachour Sami,Loschi Michael,Mohty Bilal,Saillard Colombe,Hicheri Yosr,Rouzaud Camille,Maisano Valerio,Villetard Ferdinand,Corda Evelyne D.'Incan,Charbonnier Aude,Rey Jerome,Hospital Marie-Anne,Ittel Antoine,Abbou Norman,Fanciullino Raphaelle,Dadone-Montaudié Bérengère,Vey Norbert,Venton Geoffroy,Cluzeau Thomas,Alary Anne-Sophie,Garciaz Sylvain

Publisher

Elsevier BV

Reference19 articles.

1. Azacitidine and venetoclax in previously untreated acute myeloid leukemia;DiNardo;N. Engl. J. Med,2020

2. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia;DiNardo;Blood,2019

3. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial;DiNardo;Lancet Haematol.,2020

4. Real World Use of Azacitidine and Venetoclax in Acute Myeloid Leukemia in Frontline and Relapse/Refractory Settings: A Multicentric Study from French Auraml Group;Gross;Blood,2023

5. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML;Stahl;Blood Adv.,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Molecular Features and Treatment Paradigms of Acute Myeloid Leukemia;Biomedicines;2024-08-06